

SOLIQUA[®] MOTIVATION DOCUMENT

PRESCRIBING DR DETAILS					
Name and Surname:			Practice No:		
Email address:			Tel no:		
Signature			Date:		
PATIENT DETAILS					
Name and Surname:			Gender:		
Medical aid:			Plan option:		
Member no:			Date of Birth:		
Date of diabetes diagnosis:			ICD 10 Code:		
CLINICAL PROFILE					
Latest HbA1c:		Date and result 1:		Date and result 2:	
Indicate recent weight gain in kg if applicable		Kg:		Current BMI: kg/m ²	
HbA1c levels remain above the individualized goal of <7.0% ¹ :				Yes/No	
Inadequate postprandial glucose control or glucose variability ² :				Yes/No	
COMPLICATIONS AND COMORBIDITIES					
Microvascular complication:			Cardiovascular/CKD diseases:		
Retinopathy:		Yes/No		HT Yes/No	
Nephropathy:		Yes/No		IHD Yes/No	
Neuropathy:		Yes/No		Stroke Yes/No	
Important to add this information if Soliqua will be used in combination with SGLT-2/DPP-4 ³				CKD Yes/No	
HOSPITALISATION					
Recent Diabetes related hospitalisation		Yes/No		Comment:	
HYPOGLYCEMIA RISK PROFILE					
Hypoglycemic events:		Mild Yes/No		Severe Yes/No	
Yes/No		Hypo unaware Yes/No		Frail/Risk for falls Yes/No	
CURRENT INSULIN AND ORAL DIABETES MEDICINE REGIME					
Drug:		Duration:		Dose:	
Split bolus regime		Yes/No			
PREVIOUS INSULIN AND ORAL DIABETES MEDICINE REGIME					
CONCERNS AND PREFERENCES REGARDING INJECTIONS					
Fewer injections/day		Yes/No		Smaller volumes/ injection Yes/No	
Lipohypertrophy		Yes/No		Missed dosages Yes/No	
ADDITIONAL COMMENTS					
PLEASE NOTE, IF ANY DETAILS ARE MISSING THIS WILL DELAY THE MOTIVATION PROCESS					
Please attach:			1. All pathology results within the last 6 months		
			2. Current full chronic prescription with ICD 10 codes		
			3. Recent home glucose monitoring profile if available		

1. Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(1):3-64. 2. Rosenstock J, et al. Effect of insulin glargine/lixisenatide fixed-ratio combination versus lixisenatide alone in type 2 diabetes: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):1972-1980. 3. <https://www.semDSA.org.za/for-members/guidelines>